27 sep: Resultat af fortegningsretsemission i Vestjysk Bank
27 sep: Debitormassens sammensætning for konverterbare obligationsserier,..
27-09-2017 09:00:00

ALK’s partner, Torii, gains approval for Japanese cedar SLIT-tablet in Japan

Relateret indhold
14 sep - 
ALK-Abelló/Kempen: Reducerer til "sælg" og fastholder k..
14 sep - 
ALK-Abelló: Amerikanere reducerer sats på kursfald
13 sep - 
Torsdagens aktier: Japansk udfald mod Ambu trak aktien ..
Relateret debat
22 aug - 
Der hvor jeg tror man undervurderer potentialet er hast..
22 aug - 
Den har ihvertfald lavet et GC d. 08.06.2018, og både k..
22 aug - 
Alk brager nu igennem 1200. Men hvor langt skal den op ..

 

  • CEDARCURE™ is the first SLIT-tablet to be approved for both adult and paediatric use in Japan

  • Joins the already launched MITICURE™

    (ACARIZAX® in Europe) in Torii’s allergy portfolio, effectively completing the coverage of allergies in Japan

  • ALK entitled to receive royalties on sales of CEDARCURE™

  • ALK’s financial guidance for 2017 remains unchanged

     

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Japan’s Ministry of Health, Labour and Welfare has approved the New Drug Application submitted by its partner Torii Pharmaceutical Co., Ltd., for the Japanese cedar sublingual allergy immunotherapy (SLIT) tablet, which will be branded CEDARCURE™.

 

CEDARCURE™ is based on the same SLIT-tablet technology used in ALK’s grass, ragweed and house dust mite SLIT-tablets, and was developed by Torii with support from ALK specifically for the Japanese market, where Japanese cedar pollen is a major allergen.

 

Japan is the world’s second largest market for allergy medicine after the USA. Around 25% of Japan’s population suffer from allergic rhinitis (AR), with around 70% of AR sufferers having a specific allergy to Japanese cedar pollen. Japanese cedar allergy can affect people of all ages but recent research shows that the typical age of onset is falling.

 

CEDARCURE™ has been approved for hyposensitisation therapy (allergy immunotherapy) for the treatment of Japanese cedar pollinosis (allergic rhinitis) in adults and children, and is the first SLIT-tablet to be approved for both adult and paediatric use in Japan.

 

Carsten Hellmann, ALK’s President and CEO says: “This approval marks the culmination of several years of successful R&D collaboration between ALK and Torii, a partnership that we anticipate will bring many more years of commercial return. It also means another successful approval for the SLIT-tablet technology that underpins our global range of standardised, registered allergy immunotherapy treatments, adding Japanese cedar to a range that includes grass, ragweed and house dust mite treatments, with a tree tablet to be added in the foreseeable future.”

 

ALK’s partnership with Torii was announced in 2011, and covers the development, registration and commercialisation of CEDARCURE™ as well as ALK’s house dust mite SLIT-tablet, ACARIZAX®, which was approved for adult use in Japan in 2015 and launched under the Torii brand name of MITICURE™. In March 2017, Torii also submitted a paediatric registration application for MITICURE™ based on positive Phase III clinical data.

 

A launch date for CEDARCURE™ will be announced by Torii after price and reimbursement have been agreed upon with the National Health Insurance.

 

ALK is entitled to receive royalties on the sales of CEDARCURE™ which will be booked as partner revenue from International markets. This announcement does not change ALK’s 2017 financial outlook.

 

ALK-Abelló A/S

 

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

 

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen.

Find more information at www.alk.net.

About Torii Pharmaceutical Co., Ltd.

Established in 1921,

Torii Pharmaceutical Co., Ltd., manufactures and markets pharmaceutical products in four main therapeutic areas: renal diseases and haemodialysis, skin diseases, HIV, and allergy. The company has approximately 1,000 employees, is headquartered in Tokyo and is listed on the Tokyo Stock Exchange (TSE:4551). Read more at

www.torii.co.jp

.

Attachments:

https://www.globenewswire.com/NewsRoom/AttachmentNg/330222a1-5070-401e-9302-cd22514917b5

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Alm. Brand og Topdanmark hæves til "køb" af Danske Markets - NY

24-09-2018 10:03:34
Danske Markets hæver anbefalingen af aktierne i de to forsikringsselskaber Alm. Brand og Topdanmark.I begge tilfælde er anbefalingen hævet til "køb" fra tidligere "hold", fremgår det af Bloomberg News. Kursmålet for Topdanmark-aktien er justeret op til 320 kr. fra før 300 kr., mens 12-måneders kursmålet for Alm. Brands aktie er fastholdt på 64 kr. Danske Markets gentager i øvrigt en købsanbefaling..

Aktier/tendens: Mærsk og Coloplast i fokus midt i handelskonflikt

24-09-2018 08:26:39
Coloplast og Mærsk kan komme i rampelyset mandag morgen, hvor de fortsatte handelsstridigheder mellem USA og Kina også vil være et af dagens store samtaleemner efter nye tariffer og en kinesisk afvisning af at deltage i nye handelsforhandlinger.Det tyder også på, at de danske eliteaktier skal en tur ned mandag morgen, hvor markedet igen er præget af den seneste udvikling i handelsstriden mellem US..

Danske: Moody's ser risiko for sænkning af kreditvurderingen - NY

21-09-2018 15:14:23
Moody's Investors Service er gået i gang med at kigge kreditvurderingen af Danske Bank efter i sømmene og forudser, at der er risiko for en nedjustering. Det oplyser ratinginstituttet fredag, hvor udsigten for Danske Banks kreditvurdering er sænket til "negativ" fra "stabil".Ændringen kommer, efter at banken har offentliggjort rapporten om hvidvask i sin estiske filial tidligere på ugen, skriver M..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank-investorer sætter aktien på vippen - citat
2
ECB/Nordea: Markedet gearer op til et høgeagtigt skift
3
Danske Bank er millimeter fra at udpege ny topchef - citat
4
Aktier/tendens: Mærsk og Coloplast i fokus midt i handelskonflikt
5
Aktier/middag: Ambu og Danske ryger til bunds i nervøst aktiemarked

Relaterede aktiekurser

ALK-Abelló B A/S 1.102,00 -2,5% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. september 2018 05:02:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180919.1 - EUROWEB1 - 2018-09-25 05:02:43 - 2018-09-25 05:02:43 - 1 - Website: OKAY